US supreme court halts Purdue Pharma deal that shields Sacklers from lawsuits
The US supreme court has agreed to hear a challenge by Joe Biden’s administration to the legality of OxyContin maker Purdue Pharma’s bankruptcy settlement that would shield its owners from the Sackler family from lawsuits over their role in the country’s opioid epidemic.
The court also paused bankruptcy proceedings concerning Purdue and its affiliates and said in a brief order that it would hold oral arguments in December in the administration’s appeal of a lower court’s ruling upholding the settlement. The court’s new term begins in October.
Purdue’s owners under the settlement would receive immunity in exchange for paying up to $6bn to settle thousands of lawsuits filed by states, hospitals, people who had become addicted and others who have sued the Stamford, Connecticut-based company over its misleading marketing of OxyContin.
At issue is whether US bankruptcy law allows Purdue’s restructuring to include legal protections for the Sackler family, who have not filed for personal bankruptcy.
Purdue filed for Chapter 11 bankruptcy protection from creditors in 2019 to address its debts, nearly all of which stemmed from thousands of lawsuits alleging that OxyContin helped kickstart an opioid epidemic that has caused more than 500,000 US overdose deaths over two decades.
Purdue estimates that its bankruptcy settlement, approved by a US bankruptcy judge in 2021, would provide $10bn in value to its creditors, including state and local governments, individual victims of addiction, hospitals and others who have sued the company.
The Biden administration and eight states challenged the settlement, but all of the states dropped their opposition after the Sacklers agreed to contribute more to the settlement fund.
In May, the second circuit upheld the settlement, concluding that federal bankruptcy law allows legal protections for non-bankrupt parties like the Sacklers in extraordinary circumstances.
The second circuit ruled that the legal claims against Purdue were inextricably linked to claims against its owners, and that allowing lawsuits to continue targeting the Sacklers would undermine Purdue’s efforts to reach a bankruptcy settlement.
Members of the Sackler family have denied wrongdoing but expressed regret that OxyContin “unexpectedly became part of an opioid crisis”. They said in May that the bankruptcy settlement would provide “substantial resources for people and communities in need”.
In a court filing, the administration told the supreme court that Purdue’s settlement is an abuse of bankruptcy protections meant for debtors in “financial distress,” not people like the Sacklers. According to the administration, Sackler family members withdrew $11bn from Purdue before agreeing to contribute $6bn to its opioid settlement.
The administration’s request was filed on behalf of the office of the US trustee, the justice department’s bankruptcy watchdog. An array of other stakeholders have responded in opposition to the administration’s request to halt the settlement.
A group comprising more than 60,000 people who have filed personal injury claims stemming from their exposure to Purdue opioid products told the supreme court they support the settlement, including legal immunity for members of the Sackler family.
“Regardless of how one feels about the role of the Sackler family in the creation and escalation of the opioid crisis,” the group told the justices, “the fact remains that the billions of dollars in abatement and victim compensation funds hinge on confirmation and consummation of the existing plan.”